Cell and Gene Therapy Supply Chain Software Market Revenue to Cross USD 1,329 million by 2035 | Roots Analysis

Cell and gene therapies are gradually changing the face of modern healthcare. These new regenerative therapeutic modalities have the potential to improve the treatment outcomes by providing viable therapy options for various rare diseases. Owing to their temperature-sensitive nature, it becomes increasingly important to track the biological sample material from the time of its collection, current location and therapy manufacturing. 

In order to ensure seamless execution of different tracking processes and the commercial success of such therapies, implementation of advanced software solutions for supply chain management is gaining traction among several therapy developers worldwide. As cell and advanced therapy products involve multiple stakeholders, the use of these software solutions enables real-time control over the entire supply chain, thereby, mitigating the risk of improper sample handling and effective management of patient data.

Market Segments

Based on the process component, the market is segmented into sample collection and processing component, manufacturing component, logistics component, and patient identification and treatment follow-up component.

§  The software solutions used to carry out operations in the manufacturing component will dominate the cell and gene therapy supply chain software market, capturing 40% of the overall market share, by 2035.

§  Segment for software solutions used to carry out operations in the logistics component is likely to grow at a higher CAGR of 16.6%, during the forecast period.

Based on the type of software, the market is segmented into Enterprise Manufacturing Systems (EMS), Laboratory Information Management Systems (LIMS), Inventory Management Systems (IMS), Cell Orchestration Platforms (COP), Quality Management Systems (QMS), Logistics Management Systems (LMS) and Patient Management Systems (PMS).

§  The EMS segment will dominate the cell and gene therapy supply chain software market, capturing 18% of the overall market share by 2035.

§  Cell orchestration platforms segment is likely to grow at a higher CAGR of 17%, during the forecast period.

Based on the mode of deployment, the market is segmented into on-premise deployment and cloud-based deployment.

§  Software solutions deployed on-premise capture the majority (57%) share of the overall cell and gene therapy supply chain software market in 2024.

§  The market for software solutions which can be deployed on the cloud is likely to grow at a higher CAGR of 17.2%, during the forecast period.

Based on the scale of operation, the market is segmented into clinical scale and commercial scale.

§  Software solutions used to manage operations at the clinical scale capture the majority (55%) of the overall cell and gene therapy supply chain software market in 2024.

§  The market for software solutions used to manage operations at the commercial scale is likely to grow at a higher CAGR of 20.9%, during the forecast period.

Based on the type of end-user, the market is segmented into pharmaceutical companies, cell therapy labs, hospitals / medical centers and research institutes / biobanks.

§  Pharmaceutical companies will dominate the cell and gene therapy supply chain software market, capturing 38% of the overall market share by 2035.

§  The market for software solutions used by cell therapy labs is likely to grow at a higher CAGR of 16.6%, during the forecast period.

Regional Outlook

Based on the key geographical regions, the cell and gene therapy supply chain software market can be segmented into four major regions, including North America, Europe, Asia-Pacific and Rest of the World. Led by the US, North America is anticipated to capture the majority share of the market in 2024 and this trend is likely to remain unchanged during the forecast period. 

Asia-Pacific is accounted to be the fastest-growing segment of the market. The growth of the cell and gene therapy supply chain software market in the region is driven by the growing number of clinical trials in the region for various novel personalized therapeutic modalities.

Key Report Takeaways

§  Presently, close to 100 companies claim to offer software solutions for managing the cell and gene therapy supply chain; majority of these were established post-1975

§  Presently, close to 175 cell and gene therapy supply chain software solutions are available in the market; of these, 22% are laboratory information management systems

§  Over 20% of the cell and gene therapy supply chain software solutions can be deployed both on-premises and over the cloud, offering flexibility as well as contact-less options for the end-users

§  The current market landscape of cell and gene therapy supply chain software providers is fragmented, featuring the presence of both new entrants and established players; majority (50%) of these players are based in North America

§  Foreseeing the lucrative potential, a large number of players have made investments worth over USD 3 billion, across 48 funding instances, to advance the initiatives undertaken by stakeholders in this industry

§  The growing interest in this domain is evident from the rise in partnership activity; in fact, 40 partnership deals related to cell and gene therapy supply chain software were inked in 2023 alone

§  In the short to mid-term, software solutions used to carry out operations in the manufacturing component are anticipated to capture the major share of cell and gene therapy supply chain software market, however, software solutions used in the logistics operations are expected grow at a higher CAGR during the forecast period.

Key Players

Examples of key companies engaged in the cell and gene therapy supply chain software market (the complete list of companies is available in the full report) include Azenta Life Sciences, NMDP BioTherapies, Biocair, BioLife Solutions, CareDx, Cryoport, Lonza, TraceLink, TrakCel, Veeva Systems, Emerson, LabVantage Solutions, Marken, MasterControl, QuickSTAT, Siemens, Stafa Cellular Therapy, Steiner, STEMSOFT Software, TECHNIDATA and Thermo Fisher Scientific. 

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091

Email: sales@rootsanalysis.com